Molnupiravir

DRUG20 trials

Conditions

COVID-19Coronavirus Disease (COVID-19)Covid19HealthyHepatic ImpairmentInfluenzaInfluenza InfectionInfluenza, Human

Phase 1

AGILE (Early Phase Platform Trial for COVID-19)

RecruitingNCT04746183

University of LiverpoolCovid19

Start: 2020-07-03End: 2026-07-31Target: 600Updated: 2026-01-14

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

CompletedNCT05386758

Merck Sharp & Dohme LLCRenal Impairment

Start: 2022-06-29End: 2023-03-01Updated: 2025-01-28

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

CompletedNCT05386589

Merck Sharp & Dohme LLCHepatic Impairment

Start: 2022-06-14End: 2023-01-05Updated: 2025-01-28

Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)

CompletedNCT05818124

Merck Sharp & Dohme LLCInfluenza Infection

Start: 2023-08-21End: 2024-06-28Updated: 2025-08-06

A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

CompletedNCT06615869

Merck Sharp & Dohme LLCHealthy

Start: 2023-01-20End: 2023-03-15Updated: 2025-07-11

Phase 2

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

CompletedNCT04575597

Merck Sharp & Dohme LLCCoronavirus Disease (COVID-19)

Start: 2020-10-19End: 2022-05-05Updated: 2023-06-28

Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)

TerminatedNCT04575584

Merck Sharp & Dohme LLCCoronavirus Disease (COVID-19)

Start: 2020-10-19End: 2021-08-11Updated: 2023-01-17

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

RecruitingNCT05041907

University of OxfordCOVID-19

Start: 2021-09-30End: 2027-01-01Target: 3800Updated: 2026-02-19

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

CompletedNCT05559905

Merck Sharp & Dohme LLCRespiratory Syncytial Virus

Start: 2022-11-02End: 2023-06-08Updated: 2025-07-18

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

RecruitingNCT05648448

University of OxfordInfluenza, Influenza, Human

Start: 2023-02-22End: 2027-01-01Target: 3000Updated: 2026-02-19

Assessing Antiviral Treatments in Early Symptomatic RSV

RecruitingNCT06488300

University of OxfordRespiratory Syncytial Virus, Respiratory Syncytial Virus, Human

Start: 2024-07-25End: 2027-01-01Target: 1000Updated: 2025-07-02

Phase 3

Randomised Evaluation of COVID-19 Therapy

RecruitingNCT04381936

University of OxfordSevere Acute Respiratory Syndrome

Start: 2020-03-19End: 2036-06-30Target: 70000Updated: 2024-01-05

The DAWN Antivirals Trial for Ambulatory COVID-19 Patients

TerminatedNCT04730206

KU LeuvenCovid19, SARS-CoV Infection

Start: 2021-06-15End: 2022-07-13Updated: 2022-10-03

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

CompletedNCT04939428

Merck Sharp & Dohme LLCCoronavirus Disease (COVID-19)

Start: 2021-08-11End: 2022-11-16Updated: 2024-09-26

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

RecruitingNCT06667700

Merck Sharp & Dohme LLCCoronavirus Disease (COVID-19)

Start: 2024-12-02End: 2031-01-26Target: 3082Updated: 2026-04-03

A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression

RecruitingCTIS2023-507227-36-00

Merck Sharp & Dohme LLCSARS-CoV-2 (COVID-19) infection

Start: 2025-02-21Target: 767Updated: 2026-01-20

Unknown Phase

TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2

CompletedNCT05195060

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)COVID-19

Start: 2021-12-14End: 2025-09-01Updated: 2025-12-16

Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers

CompletedNCT05412173

Valenta Pharm JSCCOVID-19, Viral Infection

Start: 2022-04-22End: 2022-06-02Updated: 2023-07-27

Effectiveness and Safety of New Oral Antivirals for COVID-19

NCT05894603

Universidade do PortoCOVID-19

Start: 2022-08-01End: 2024-06-30Updated: 2023-12-18

Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.

Active, not recruitingNCT06223932

Serap YavuzCOVID-19, SARS-CoV-2 Infection

Start: 2022-07-07End: 2024-02-29Target: 2600Updated: 2024-01-25

2026-03-18

LC-MS/MS Method Validation for Quantification of Nirmatrelvir in Human Plasma.

2025-11-17

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

2025-10-101 citations

Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial.

2025-10-09

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-08-282 citations

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-05-151 citations

A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus.

2025-04-021 citations

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study

Open Forum Infectious Diseases2025-03-262 citations

Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study

Clinical Trials2025-03-021 citations

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-02-124 citations

Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants—a randomized, open-label, three-period, crossover study

Antimicrobial Agents and Chemotherapy2025-02-063 citations

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).

2025-01-183 citations

Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment

Clinical and Translational Science2024-11-271 citations

Optimal dose and safety of intravenous favipiravir in hospitalized patients with SARS‐COV‐2: A phase I, open‐label, dose‐escalating, randomized controlled study

British Journal of Clinical Pharmacology2024-09-01

Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza.

2024-08-016 citations

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England

Trials2024-06-294 citations

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).

2024-04-2410 citations

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Microbiology Spectrum2024-02-011 citations

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2024-01-317 citations

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

2024-01-2218 citations

50 more papers not shown

Molnupiravir

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Unknown Phase

Related Papers